Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study

References

• Health Action International: Biosimilar Insulin Regulatory Profile [Internet]. Amsterdam (The Netherlands): Health Action International, April 2017; [cited 2019 May 28]. Available from: http://haiweb.org/wp-content/uploads/2017/04/Regulatory_Report_ACCISS_2017.pdf.
   Google Scholar
• Yamada T, Kamata R, Ishinohachi K, et al. Biosimilar vs originator insulins: systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(7):1787–1792.
   PubMed Web of Science ®Google Scholar
• Heinemann L. Biosimilar insulin and costs: what can we expect? J Diabetes Sci Technol. 2016;10(2):457–462.
   Google Scholar
• Eli Lilly and Company: FDA grants tentative approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection) [Internet]. Indianapolis (IN): Eli Lilly and Company, 2014, Aug 18; [cited 2019 May 28]. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=866751
   Google Scholar
• European Medicines Agency: Abasaglar (previously Abasria) [Internet]. London (United Kingdom): European Medicines Agency, 2014, Oct 14; [cited 2019 May 28]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002835/human_med_001790.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Byrd RA, Blackbourne JL, Schultze AE, et al. Comparative subchronic toxicity studies in rats of LY2963016 (LY), an insulin glargine product, with USA sourced Lantus® (US-L) and EU-sourced Lantus® (EU-L). Toxicologist. 2014;138:1650.
   Google Scholar
• Linnebjerg H, Lam EC, Zhang X, et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes Metab. 2017;19(1):33–39.
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Dia Care. 2015;38(12):2226–2233.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lam ECQ, Seger ME, et al. LY2963016 insulin glargine and insulin glargine (Lantus) produce comparable pharmacokinetics and pharmacodynamics at two dose levels. Clin Pharmacol Drug Dev. 2017;6(6):556–563.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration: Drug Approval Package: Lantus (Insulin Glargine [rDNA Origin]). NDA #21-081 2000 [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. 2001, Nov 20; [cited 2019 May 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus.cfm
   Google Scholar
• Nishiyama H, Shingaki T, Suzuki Y, et al. Similar intrapatient blood glucose variability with LY2963016 and Lantus® insulin glargine in patients with type 1 (T1D) or type 2 diabetes, including a Japanese T1D subpopulation. Diabetes Ther. 2018;9(4):1469–1476.
   PubMed Web of Science ®Google Scholar
• Blevins TC, Dahl D, Rosenstock J, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17(8):726–733.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734–741.
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
   PubMed Web of Science ®Google Scholar
• Hirose T, Chen CC, Ahn KJ, et al. Use of insulin glargine 100 U/mL for the treatment of type 2 diabetes mellitus in East Asians: a review. Diabetes Ther. 2019;10(3):805–833.
   PubMed Web of Science ®Google Scholar
• Haneda M, Noda M, Origasa H, et al. Japanese Clinical Practice Guideline for Diabetes 2016. J Diabetes Investig. 2018;9(3):657–697.
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Wolden ML, Hyllested-Winge J, et al. Diabetes management and daily functioning burden of non‐severe hypoglycemia in Japanese people treated with insulin. J Diabetes Investig. 2017;8(6):776–782.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Tsukube S, Ikeda Y, et al. Safety and efficacy of combination therapy with insulin glargine and oral hypoglycaemic agents including DPP-4 inhibitors in Japanese T2DM patients: ALOHA 2 study, a post-marketing surveillance for Lantus®. J Diabetes Mellitus. 2014;04(04):273–289.
   Google Scholar
• Ilag LL, Costigan TM, Deeg MA, et al. Clinical outcomes of patients with diabetes who exhibit upper-quartile insulin antibody responses after treatment with LY2963016 or Lantus® insulin glargine. Diabetes Ther. 2017;8(3):545–554.
   PubMed Web of Science ®Google Scholar
• Pollom RK, Costigan T, Lacaya LB, et al. Similar efficacy and safety of Basaglar® and Lantus® in patients with type 2 diabetes in age groups (<65 years, ≥65 years): a post hoc analysis from the ELEMENT-2 study. Diabetes Ther. 2018;9(2):827–837.
   PubMed Web of Science ®Google Scholar
• Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes and Needs (DAWN) JAPAN study. PLoS One. 2012;7(6):e36361.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Hessler D, et al. Identifying solutions to psychological insulin resistance: an international study. J Diabetes Complications. 2019;33(4):307–314.
   PubMed Web of Science ®Google Scholar
• Okazaki K, Shingaki T, Cai Z, et al. Successful healthcare provider strategies to overcome psychological insulin resistance in Japanese patients with type 2 diabetes. Diabetes Ther. 2019;10(5):1823–1834.
   PubMed Web of Science ®Google Scholar
• Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25(9):771–782.
   PubMed Web of Science ®Google Scholar
• Jeong IK, Chung CH, Zhou Z, et al. Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus. J Diabetes. 2017;9(4):396–404.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Dia Care. 2014;37(12):3235–3243.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18(4):366–374.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/mL provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17(3):254–260.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y, Fukushima M, et al. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602.
   PubMed Web of Science ®Google Scholar